COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries

Eng Hooi Tan; Anthony G. Sena; Albert Prats-Uribe; Seng Chan You; Waheed Ul Rahman Ahmed; Kristin Kostka; Christian Reich; Scott L. Duvall; Kristine E. Lynch; Michael E. Matheny; Talita Duarte-Salles; Sergio Fernandez Bertolin; George Hripcsak; Karthik Natarajan; Thomas Falconer; Matthew Spotnitz; Anna Ostropolets; Clair Blacketer; Thamir M. Alshammari; Heba Alghoul; Osaid Alser; Jennifer C.E. Lane; Dalia M. Dawoud; Karishma Shah; Yue Yang; Lin Zhang; Carlos Areia; Asieh Golozar; Martina Recalde; Paula Casajust; Jitendra Jonnagaddala; Vignesh Subbian; David Vizcaya; Lana Y.H. Lai; Fredrik Nyberg; Daniel R. Morales; Jose D. Posada; Nigam H. Shah; Mengchun Gong; Arani Vivekanantham; Aaron Abend; Evan P. Minty; Marc Suchard; Peter Rijnbeek; Patrick B. Ryan; Daniel Prieto-Alhambra

doi:10.1093/rheumatology/keab250

COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries

Eng Hooi Tan, Anthony G. Sena, Albert Prats-Uribe, Seng Chan You, Waheed Ul Rahman Ahmed, Kristin Kostka, Christian Reich, Scott L. Duvall, Kristine E. Lynch, Michael E. Matheny, Talita Duarte-Salles, Sergio Fernandez Bertolin, George Hripcsak, Karthik Natarajan, Thomas Falconer, Matthew Spotnitz, Anna Ostropolets, Clair Blacketer, Thamir M. Alshammari, Heba AlghoulOsaid Alser, Jennifer C.E. Lane, Dalia M. Dawoud, Karishma Shah, Yue Yang, Lin Zhang, Carlos Areia, Asieh Golozar, Martina Recalde, Paula Casajust, Jitendra Jonnagaddala, Vignesh Subbian, David Vizcaya, Lana Y.H. Lai, Fredrik Nyberg, Daniel R. Morales, Jose D. Posada, Nigam H. Shah, Mengchun Gong, Arani Vivekanantham, Aaron Abend, Evan P. Minty, Marc Suchard, Peter Rijnbeek, Patrick B. Ryan, Daniel Prieto-Alhambra^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

37 Citations (Scopus)

32 Downloads (Pure)

Abstract

OBJECTIVE: Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. METHODS: A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization. RESULTS: We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%). CONCLUSION: Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.

Original language	English
Pages (from-to)	SI37-SI50
Journal	Rheumatology (Oxford, England)
Volume	60
Issue number	SI
Early online date	16 Mar 2021
DOIs	https://doi.org/10.1093/rheumatology/keab250
Publication status	Published - 1 Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Access to Document

10.1093/rheumatology/keab250Licence: CC BY

COVID-19 in patients with autoimmune diseases, characteristics and outcomes in a multinational network of cohorts across three countriesFinal published version, 614 KBLicence: CC BY

Cite this

Tan, E. H., Sena, A. G., Prats-Uribe, A., You, S. C., Ahmed, W. U. R., Kostka, K., Reich, C., Duvall, S. L., Lynch, K. E., Matheny, M. E., Duarte-Salles, T., Bertolin, S. F., Hripcsak, G., Natarajan, K., Falconer, T., Spotnitz, M., Ostropolets, A., Blacketer, C., Alshammari, T. M., ... Prieto-Alhambra, D. (2021). COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford, England), 60(SI), SI37-SI50. https://doi.org/10.1093/rheumatology/keab250

@article{17e095495a55449a8ece02dd03da9530,

title = "COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries",

abstract = "OBJECTIVE: Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. METHODS: A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization. RESULTS: We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%). CONCLUSION: Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.",

author = "Tan, {Eng Hooi} and Sena, {Anthony G.} and Albert Prats-Uribe and You, {Seng Chan} and Ahmed, {Waheed Ul Rahman} and Kristin Kostka and Christian Reich and Duvall, {Scott L.} and Lynch, {Kristine E.} and Matheny, {Michael E.} and Talita Duarte-Salles and Bertolin, {Sergio Fernandez} and George Hripcsak and Karthik Natarajan and Thomas Falconer and Matthew Spotnitz and Anna Ostropolets and Clair Blacketer and Alshammari, {Thamir M.} and Heba Alghoul and Osaid Alser and Lane, {Jennifer C.E.} and Dawoud, {Dalia M.} and Karishma Shah and Yue Yang and Lin Zhang and Carlos Areia and Asieh Golozar and Martina Recalde and Paula Casajust and Jitendra Jonnagaddala and Vignesh Subbian and David Vizcaya and Lai, {Lana Y.H.} and Fredrik Nyberg and Morales, {Daniel R.} and Posada, {Jose D.} and Shah, {Nigam H.} and Mengchun Gong and Arani Vivekanantham and Aaron Abend and Minty, {Evan P.} and Marc Suchard and Peter Rijnbeek and Ryan, {Patrick B.} and Daniel Prieto-Alhambra",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.",

year = "2021",

month = oct,

day = "1",

doi = "10.1093/rheumatology/keab250",

language = "English",

volume = "60",

pages = "SI37--SI50",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "SI",

}

Tan, EH, Sena, AG, Prats-Uribe, A, You, SC, Ahmed, WUR, Kostka, K, Reich, C, Duvall, SL, Lynch, KE, Matheny, ME, Duarte-Salles, T, Bertolin, SF, Hripcsak, G, Natarajan, K, Falconer, T, Spotnitz, M, Ostropolets, A, Blacketer, C, Alshammari, TM, Alghoul, H, Alser, O, Lane, JCE, Dawoud, DM, Shah, K, Yang, Y, Zhang, L, Areia, C, Golozar, A, Recalde, M, Casajust, P, Jonnagaddala, J, Subbian, V, Vizcaya, D, Lai, LYH, Nyberg, F, Morales, DR, Posada, JD, Shah, NH, Gong, M, Vivekanantham, A, Abend, A, Minty, EP, Suchard, M, Rijnbeek, P, Ryan, PB & Prieto-Alhambra, D 2021, 'COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries', Rheumatology (Oxford, England), vol. 60, no. SI, pp. SI37-SI50. https://doi.org/10.1093/rheumatology/keab250

TY - JOUR

T1 - COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries

AU - Tan, Eng Hooi

AU - Sena, Anthony G.

AU - Prats-Uribe, Albert

AU - You, Seng Chan

AU - Ahmed, Waheed Ul Rahman

AU - Kostka, Kristin

AU - Reich, Christian

AU - Duvall, Scott L.

AU - Lynch, Kristine E.

AU - Matheny, Michael E.

AU - Duarte-Salles, Talita

AU - Bertolin, Sergio Fernandez

AU - Hripcsak, George

AU - Natarajan, Karthik

AU - Falconer, Thomas

AU - Spotnitz, Matthew

AU - Ostropolets, Anna

AU - Blacketer, Clair

AU - Alshammari, Thamir M.

AU - Alghoul, Heba

AU - Alser, Osaid

AU - Lane, Jennifer C.E.

AU - Dawoud, Dalia M.

AU - Shah, Karishma

AU - Yang, Yue

AU - Zhang, Lin

AU - Areia, Carlos

AU - Golozar, Asieh

AU - Recalde, Martina

AU - Casajust, Paula

AU - Jonnagaddala, Jitendra

AU - Subbian, Vignesh

AU - Vizcaya, David

AU - Lai, Lana Y.H.

AU - Nyberg, Fredrik

AU - Morales, Daniel R.

AU - Posada, Jose D.

AU - Shah, Nigam H.

AU - Gong, Mengchun

AU - Vivekanantham, Arani

AU - Abend, Aaron

AU - Minty, Evan P.

AU - Suchard, Marc

AU - Rijnbeek, Peter

AU - Ryan, Patrick B.

AU - Prieto-Alhambra, Daniel

PY - 2021/10/1

Y1 - 2021/10/1

N2 - OBJECTIVE: Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. METHODS: A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization. RESULTS: We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%). CONCLUSION: Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.

AB - OBJECTIVE: Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. METHODS: A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization. RESULTS: We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%). CONCLUSION: Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.

UR - http://www.scopus.com/inward/record.url?scp=85111765204&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keab250

DO - 10.1093/rheumatology/keab250

M3 - Article

C2 - 33725121

AN - SCOPUS:85111765204

SN - 1462-0324

VL - 60

SP - SI37-SI50

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - SI

ER -

COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this